Environmental risk factors for Parkinson's disease and parkinsonism: The Geoparkinson study

University of Aberdeen, Aberdeen, Scotland, United Kingdom
Occupational and environmental medicine (Impact Factor: 3.27). 11/2007; 64(10):666-72. DOI: 10.1136/oem.2006.027003
Source: PubMed


To investigate the associations between Parkinson's disease and other degenerative parkinsonian syndromes and environmental factors in five European countries.
A case-control study of 959 prevalent cases of parkinsonism (767 with Parkinson's disease) and 1989 controls in Scotland, Italy, Sweden, Romania and Malta was carried out. Cases were defined using the United Kingdom Parkinson's Disease Society Brain Bank criteria, and those with drug-induced or vascular parkinsonism or dementia were excluded. Subjects completed an interviewer-administered questionnaire about lifetime occupational and hobby exposure to solvents, pesticides, iron, copper and manganese. Lifetime and average annual exposures were estimated blind to disease status using a job-exposure matrix modified by subjective exposure modelling. Results were analysed using multiple logistic regression, adjusting for age, sex, country, tobacco use, ever knocked unconscious and family history of Parkinson's disease.
Adjusted logistic regression analyses showed significantly increased odds ratios for Parkinson's disease/parkinsonism with an exposure-response relationship for pesticides (low vs no exposure, odds ratio (OR) = 1.13, 95% CI 0.82 to 1.57, high vs no exposure, OR = 1.41, 95% CI 1.06 to 1.88) and ever knocked unconscious (once vs never, OR = 1.35, 95% CI 1.09 to 1.68, more than once vs never, OR = 2.53, 95% CI 1.78 to 3.59). Hypnotic, anxiolytic or antidepressant drug use for more than 1 year and a family history of Parkinson's disease showed significantly increased odds ratios. Tobacco use was protective (OR = 0.50, 95% CI 0.42 to 0.60). Analyses confined to subjects with Parkinson's disease gave similar results.
The association of pesticide exposure with Parkinson's disease suggests a causative role. Repeated traumatic loss of consciousness is associated with increased risk.


Available from: Anthony Seaton
  • Source
    • "Therefore , the possibility remains that psychoactive drugs can cause permanent damage to the nigrostriatal pathway. Studies have reported that antidepressant use is associated with a high risk for developing PD (Alonso et al., 2009; Dick et al., 2007). In particular, tricyclic antidepressants (TCAs) have been reported to reduce the viability of various types of cells in vitro (Haller et al., 2007; Huang et al., 2007; Kitagawa et al., 2006; Lirk et al., 2006) and in vivo (Estebe and Myers, 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent studies report that a history of antidepressant use is strongly correlated with the occurrence of Parkinson's disease (PD). However, it remains unclear whether antidepressant use can be a causative factor for PD. In the present study, we examined whether tricyclic antidepressants amitriptyline and desipramine can induce dopaminergic cell damage, both in vitro and in vivo. We found that amitriptyline and desipramine induced mitochondria-mediated neurotoxicity and oxidative stress in SH-SY5Y cells. When injected into mice on a subchronic schedule, amitriptyline induced movement deficits in the pole test, which is known to detect nigrostriatal dysfunction. In addition, the number of tyrosine hydroxylase-positive neurons in the substantia nigra pars compacta was reduced in amitriptyline-injected mice. Our results suggest that amitriptyline and desipramine may induce PD-associated neurotoxicity.
    Moleculer Cells 08/2015; 38(8). DOI:10.14348/molcells.2015.0131 · 2.09 Impact Factor
  • Source
    • "The cause of PD is unknown, though at least one subtype demonstrates a genetic linkage (for a review, see Corti et al. 2011). There is also evidence suggesting that occupational pesticide exposure is a risk factor for PD (Gorell et al. 1998; Betarbet et al. 2000; Firestone et al. 2005, 2010; Dick et al. 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Parkinson's disease (PD) is a neurodegenerative disorder associated with debilitating motor, posture, and gait abnormalities. Human studies recording local field potentials within the subthalamic nucleus and scalp-based electroencephalography have shown pathological beta synchronization throughout the cortical-basal ganglia motor network in PD. Suppression of such pathological beta synchronization has been associated with improved motor function, which may explain the effectiveness of deep-brain stimulation. We used magnetoencephalography (MEG) to investigate neural population-level beta responses, and other oscillatory activity, during a motor task in unmedicated patients with PD and a matched group of healthy adults. MEG is a noninvasive neurophysiological technique that permits the recording of oscillatory activity during movement planning, execution, and termination phases. Each of these phases was independently examined using beamforming to distinguish the brain areas and movement phases, where pathological oscillations exist during motor control. Patients with PD exhibited significantly diminished beta desynchronization compared with controls prior to and during movement, which paralleled reduced alpha desynchronization. This study is the first to systematically investigate neural oscillatory responses in PD during distinct stages of motor control (e.g. planning, execution, and termination) and indicates that these patients have significant difficulty suppressing cortical beta synchronization during movement planning, which may contribute to their diminished movement capacities.
    Cerebral Cortex 10/2014; 24:2669–2678. DOI:10.1093/cercor/bht121 · 8.67 Impact Factor
  • Source
    • "It has been suggested that chronic Mn exposure in doses insufficient to induce manganism may be toxic to the SN rather than the globus pallidus (GP) and can increase the risk of developing idiopathic PD [43]. Several epidemiological studies have found an association between Mn exposure and risk of idiopathic PD [36,37,44–49], however other studies do not support such an association [35] [50] [51]. Some reviews [52] [53] and one meta-analysis [54] concluded that available data argue against a relationship between Mn exposure and PD. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Impaired cellular homeostasis of metals, particularly of Cu, Fe and Mn may trigger neurodegeneration through various mechanisms, notably induction of oxidative stress, promotion of α-synuclein aggregation and fibril formation, activation of microglial cells leading to inflammation and impaired production of metalloproteins. In this article we review available studies concerning Fe, Cu and Mn in Parkinson's disease and Wilson's disease. In Parkinson's disease local dysregulation of iron metabolism in the substantia nigra (SN) seems to be related to neurodegeneration with an increase in SN iron concentration, accompanied by decreased SN Cu and ceruloplasmin concentrations and increased free Cu concentrations and decreased ferroxidase activity in the cerebrospinal fluid. Available data in Wilson's disease suggest that substantial increases in CNS Cu concentrations persist for a long time during chelating treatment and that local accumulation of Fe in certain brain nuclei may occur during the course of the disease. Consequences for chelating treatment strategies are discussed.
    Journal of Trace Elements in Medicine and Biology 06/2014; DOI:10.1016/j.jtemb.2014.05.007 · 2.37 Impact Factor
Show more